GlassScriptPhysician profile
Karr Farrell Johnson
NPI 1205160587
$2,621.31
in general payments reported to CMS, 2019-2025
24 companies · $757 in 2025
The $757 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.52 · 2022: $276 · 2023: $427 · 2024: $1,146 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $513.94 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $371.16 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $273.14 | 2022-2025 | |
| Pfizer INC. | $264.34 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $151.49 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Aimmune Therapeutics, INC. | $148.29 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $146.96 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.47 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.53 | 2022-2025 | Jardiance, Synjardy |
| Amgen INC. | $90.71 | 2023-2025 | Krystexxa, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $85.70 | 2024-2025 | Camzyos, Eliquis |
| Exact Sciences Corporation | $71.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $39.03 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $36.44 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $36.23 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $29.97 | 2022-2023 | Doc Band |
| Sanofi Pasteur INC. | $29.95 | 2023 | |
| Abbott Laboratories | $24.28 | 2022 | |
| Corcept Therapeutics | $23.39 | 2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $22.96 | 2022 | |
| Inspire Medical Systems, INC. | $17.45 | 2025 | Inspire |
| Cardiovascular Systems INC. | $15.52 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $11.12 | 2022 | |
| Phathom Pharmaceuticals, INC. | $9.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karr Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.